Verona Pharma plc (VRNA)

15.72 0.00 (0.00%) At close: 04:00PM EDT

Verona Pharma plc

3 More London Riverside
London SE1 2RE
United Kingdom
44 20 3283 4200
https://www.veronapharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 79

Key executives

Name	Title	Pay	Exercised	Year born
Dr. David S. Zaccardelli Pharm.D.	President, CEO & Executive Director	1.27M	N/A	1964
Mr. Mark W. Hahn	Chief Financial Officer	858.29k	N/A	1963
Dr. Kathleen A. Rickard M.D.	Chief Medical Officer	650.83k	N/A	1958
Mr. Andrew Fisher	General Counsel	N/A	N/A	1970
Ms. Victoria Stewart	Director of Communications	N/A	N/A	N/A
Mr. Matthew Casbon	VP of Sales, Marketing & Training	N/A	N/A	N/A
Ms. Ostra Jewell	Senior Vice President of Human Resources	N/A	N/A	N/A
Dr. Tara Rheault M.P.H., Ph.D.	Chief Development Officer	N/A	N/A	1977
Mr. Christopher Martin	Chief Commercial Officer	N/A	N/A	N/A
Ms. Caroline Diaz	Senior Vice President of Regulatory Affairs	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.

Corporate governance

Verona Pharma plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.